Brokers Set Expectations for INKT FY2029 Earnings

MiNK Therapeutics, Inc. (NASDAQ:INKT) – Equities research analysts at HC Wainwright issued their FY2029 earnings per share estimates for shares of MiNK Therapeutics in a report issued on Tuesday, February 25th. HC Wainwright analyst E. Bodnar forecasts that the company will post earnings of ($0.02) per share for the year. HC Wainwright currently has a “Buy” rating and a $35.00 price target on the stock. The consensus estimate for MiNK Therapeutics’ current full-year earnings is ($2.75) per share.

Separately, Robert W. Baird cut their target price on MiNK Therapeutics from $80.00 to $40.00 and set an “outperform” rating on the stock in a research note on Friday, November 15th.

MiNK Therapeutics Stock Performance

Shares of INKT opened at $9.37 on Wednesday. The stock has a 50 day simple moving average of $8.37 and a 200 day simple moving average of $7.73. MiNK Therapeutics has a 52-week low of $4.56 and a 52-week high of $19.00. The firm has a market capitalization of $37.13 million, a PE ratio of -2.40 and a beta of 0.17.

About MiNK Therapeutics

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.